Media headlines about biOasis Technologies (CVE:BTI) have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 6,000 blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. biOasis Technologies earned a news impact score of 1.44 on their scale. InfoTrie also gave news headlines about the company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the near term.
CVE:BTI traded down C$0.01 during trading hours on Thursday, hitting C$0.33. 96,000 shares of the company traded hands, compared to its average volume of 49,486. biOasis Technologies has a twelve month low of C$0.26 and a twelve month high of C$1.02.
biOasis Technologies (CVE:BTI) last released its earnings results on Monday, July 30th. The company reported C($0.03) EPS for the quarter. The company had revenue of C$0.05 million for the quarter. biOasis Technologies had a negative net margin of 869.82% and a negative return on equity of 178.97%.
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
Receive News & Ratings for biOasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biOasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.